<DOC>
	<DOCNO>NCT00488306</DOCNO>
	<brief_summary>In light tigecycline 's activity resistant bacteria , tigecycline may represent viable new therapy complicate intra-abdominal infection .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Tigecycline Hospitalized Patients With cIAI</brief_title>
	<detailed_description>To evaluate efficacy safety tigecycline treat complicate intra-abdominal infection hospitalize patient . Both clinical response profile microbiological response profile assess . The primary endpoint clinical response within microbiological evaluable population test-of-cure assessment .</detailed_description>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Hospitalized male female patient great equal 18 year age . Patients must candidate laparotomy , laparoscopy intraabdominal abscess . Patients complicate intraabdominal infection : intraabdominal abscess ; intraabdominal abscess ( include liver spleen ) develop postoperative patient receive &gt; 48 hour less equal 5 day nonstudy antibiotic . An intraabdominal culture must obtain infected site . appendicitis complicate perforation ( grossly visible ) abscess and/or periappendiceal abscess ; perforate diverticulitis complicate abscess formation fecal contamination ; complicate cholecystitis evidence perforation empyema ; perforation large small intestine abscess , fecal contamination ; purulent peritonitis peritonitis associate fecal contamination ; gastric duodenal ulcer perforation symptom last least 24 hour prior operation ; traumatic bowel perforation symptom last least 12 hour prior operation . Patients concomitant condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy followup visit could complete . Active treat leukemia systemic malignancy require treatment chemotherapy , immunotherapy , radiation therapy antineoplastic therapy within past 3 month , metastatic malignancy abdomen life expectancy le 6 month . Anticipated length antibiotic therapy le 5 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Tigecycline</keyword>
	<keyword>Complicated intra-abdominal infection</keyword>
	<keyword>cIAI</keyword>
</DOC>